Vaginal Microbiocenosis Features in HIV-positive Women of Fertile Age

Main Article Content

Anait Yuryevna Marianian
Maria Alexandrovna Rashidova
Lyubov Ilinichna Kolesnikova

Abstract

Aim and Objective of Our Study: The aim and objective of our study is to analyze the research data that has been studying the effect of HIV infection on vaginal microbiocenosis and further, to determine the differences in dysbiotic disorders in seronegative and seropositive women. We have also assessed the effect of vaginal microbiota on pre-exposure prophylaxis of HIV.

Materials and Methods: Evaluation of the Russian and other countries results on the microbiota of HIV-positive women studies, published in international databases.

Results: The analysis of the research data aimed at studying the effect of HIV infection on the vaginal microbiocenosis indicates that dysbiotic disorders in HIV-infected patients are significantly more frequent. It has been revealed that the atypical clinical picture of changes in the vaginal microbiocenosis prevails. It has been noted that there is a correlation of vaginal microbiocenosis in HIV-positive women and indicators of systemic immunity, CD4 + cell levels.

Conclusion: Based on analysis of published in international databases Russian and other countries studies results on the HIV-positive women microbiota, it was found that there is a need for additional studies of the qualitative and quantitative composition of the microbiota of HIV-positive women. It is need to assess the of the vaginalmicrobiotaand other possible connected factors ability to change the concentration of antiretroviral drugs.

Keywords:
Vaginalmicrobiocenosis, HIV infection, dysbiotic disorders.

Article Details

How to Cite
Marianian, A. Y., Rashidova, M. A., & Kolesnikova, L. I. (2020). Vaginal Microbiocenosis Features in HIV-positive Women of Fertile Age. Journal of Pharmaceutical Research International, 32(23), 78-84. https://doi.org/10.9734/jpri/2020/v32i2330792
Section
Review Article

References

AIDS center. Irkutsk region. Express Information; 2019. Available:http://aids38.ru/special/stat/

Leshchenko O, Marianian A, Timofeeva E, Atalyan A, Balochova T, Plotnicova Y, Suturina L. HIV infection in men and women of repro-ductive age. Alcoholism: Clinical and Experimental Research. 2017; 41(6):150.

Marianian A, Timofeeva E, Atalyan A, Leshchenko O, Suturina L, Balachova T. Alcohol use, pregnancy planning, and reproductive health concerns in people living with HIV/AIDS in Russia. Alcoholism: Clinical and Experimental Research. 2018; 42(6):76-79.

Yankovsky DS, Dyment GS. Use of probiotics to improve women's reproductive health. Women's Health. 2008;2:161-170.

Plakhova KI, Gomberg MA, Atroshkina ME. The role of Atopobium vaginae in bacterial vaginosis recurrence. Bulletin of Dermatology and Venereology. 2007;5:10-13.

Rakhmatulina MR, Blahovec I. Bacterial vaginosis, associated with Atopobium vaginae: Modern principles of diagnosis and therapy. Obstetrics and Gynecology. 2012;3:88–92.

Ferris MJ, Masztal A, Aldridge KE, Fortenberry JD, Fidel PL. Jr., Martin DH. Association of Atopobium vaginae, a recently described metronidazole resistant anaerobe, with bacterial vaginosis. BMC Infectious Diseases. 2004;4:5–8.

Verhelst R, Verstraelen H, Claeys G, Temmerman M, Vaneechoutte M. Culture-independent analysis of vaginal microflora: The unrecog-nized association of Atopobium vaginae with bacterial vaginosis. American Journal of Obstetrics and Gynecology. 2004;191(4):1130–1132.

McGregor J, FrenchL. Bacterial vaginosis in pregnancy.Obstetrical and Gynecology Survey. 2000;55:1–19.

Nunn KL, Wang YY, Harit D, Humphrys MS, Ma B, Cone R, et al. Enhanced trapping of HIV-1 by human cervicovaginal mucus is associated with Lactobacillus crispatus-dominant microbiota. mBio. 2015;6(5):01084–01015.

Hill JE, Goh SH, Money DM, Doyle M, Li A, Crosby WL, Links M, et al. Characterization of vaginal microflora of healthy, nonpreg-nant women by haperonin-60 sequence-based methods. American Journal of Obstetrics and Gynecology. 2005;193:682–692.

Kolesnikova LI, Darenskaya MA, Rashidova MA, Sholokhov LF, Grebenkina LA, Leshchenko OYA, Timofeeva EV. Evaluation of oxidative stress indicators in women with HIV mono-and co -infection. Infectious diseases. 2016;14(1): 138.

Kolesnikova L, Darenskaya M, Grebenkina L, Timofeeva E, Leshenko O, Semenova N, Kurashova N, Vanteeva O. Oxidative stress parame-ters in women with HIV and HIV/hepatitis B and/or C co-infection. Journal of AIDS and Clinical Research. 2014;5(11):5–11.

Monaco CL, Gootenberg DB, Zhao G, Handley SA, Ghebremi-chael MS, Lim ES, et al. Altered virome and bacterial microbiome in human immunodeficiency virus-associated acquired immunode-ficiency syndrome. Cell Host & Microbe. 2016;19(3):311-322.

Medvedeva OA, Korolev VA, Avdeeva YuA. State of colon microbiocenosis and pro-oxidant-antioxidant balance of colonocytes in experimental dysbiosis and prevention with mexidol. Scientific Bulletin of the Belgorod state University. Series: Medicine. Pharmacy. 2017;5(254):134–140.

Kolesnikova LI, Kolesnikov SI, Darenskaya MA, Grebenkina LA, Nikitina OA, Lazareva LM, Suturina LV, Danusevich IN, Druzhinina EB, Semendyaev AA. Activity of LPO processes in women with polycystic ovarian syndrome and infertility. Bulletin of Experimental Biology and Medicine. 2017;162:320-322.

Kolesnikova LI, Darenskaya MA, Kolesnikov SI. free radical oxidation: A pathophysiologist's view. Bulletin of Siberian Medicine. 2017:16(4):16-29.

Christel C, Daniel JS, Aubrey GB, Alice LL, Shannon AA, Kerrie L, Mc C. et al. Associations of the vaginal microbiota with HIV infec-tion, bacterial vaginosis and demographic factors. AIDS. 2017;31(7): 895–904.

Christina G, Melis NA, Scott AH. Lactobacillus-deficient cervicovag-inal bacterial communities are associated with increased HIV acqui-sition in young south african women published in final edited form as: AIDS. 2017;31(7):895–904. DOI: 10.1097/QAD.0000000000001421

Atashili J, Poole C, Ndumbe PM, Adimora AA, Smith JS. Bacterial vaginosis and HIV acquisition: A meta-analysis of published studies. AIDS. 2008;22(12):1493–1501. DOI: 10.1097/QAD.0b013e3283021a37

Passmore JAS, Jaspan HB, Masson L. Genital inflammation, im-mune activation and risk of sexual HIV acquisition. Curr Opin HIV AIDS. 2016;11(2):156–62. DOI: 10.1097/COH.0000000000000232

Masese L, Baeten JM, Richardson BA, Bukusi E, John-Stewart G, Graham Sm. et al. Changes in the contribution of genital tract infec-tions to HIV acquisition among Kenyan high-risk women from 1993 to 2012. AIDS. 2015;29(9):1077–85. DOI: 10.1097/QAD.0000000000000646

Gosmann C, Anahtar MN, Handley SA, Farcasanu M, Abu-Ali G, Bowman BA. et al. Lactobacillus-deficient cervicovaginal bacterial communities are associated with increased HIV acquisition in young South African women. Immunity. 2017;46(1):29–37. DOI: 10.1016/j.immuni.2016.12.013

Coleman JS, Hitti J, Bukusi EA, Mwachari C, Muliro A, Nguti R, et al. Infectious correlates of HIV-1 shedding in the female upper and lower genital tracts. AIDS. 2007; 21:755–759.

Martin D. The microbiota of the vagina and its influence on women's health and disease. American Journal of the Medical Sciences. 2012;343(1):2–9.

Mirmonsef P, Krass L, Landay A. The role of bacterial vaginosis and trichomonas in HIV transmission across the female genital tract.Curr. HIV Res. 2012;10:202–210.

Mbizvo EM, Msuya SE, Stray-Pedersen B. HIV seroprevalence and its associations with the other reproductive tract infections in asympto-matic women in Harare, Zimbabwe. Int J STD AIDS. 2001;12:524–531.

Eade CR, Diaz C, Chen S, Cole AL, Cole AM. HIV-enhancing factors are secreted by reproductiveepithelia upon inoculation with bacterial vaginosis-associated bacteria. Protein PeptLett. 2015;22:672–680.

Jespers V, Crucitti T, van de Wijgert J, Vaneechoutte M, Delany-Moretlwe S, Mwaura MA. DNA tool for early detection of vaginal dysbiosis in African women. Res Microbiol. 2015;11:180–181.

Adimora AA, Ramirez C, Auerbach JD, Aral SO, Hodder S, Wingood G. et al. Preventing HIV infection in women. J AcquirIm-mune Defic Syndr. 2013;63(02): 168–173. DOI: 10.1097/QAI.0b013e318298a166

Caceres CF, O’Reilly KR, Mayer KH, Baggaley R. PrEPimplemen-tation: Moving from trials to policy and practice. Jint AIDS Soc. 2015;18(4):202–222. DOI: 10.7448/IAS.18.4.20222

Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in het-erosexual men and women. N Engl J Med. 2012;367(5):399–410. DOI: 10.1056/NEJMoa1108524

Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM. et al. Antiretroviral preexposure prophylaxis for heter-osexual HIV transmission in Botswana. NEngl J Med. 2012;367(5):423–434. DOI: 10.1056/NEJMoa1110711

Baeten JM, Palanee-Phillips T, Brown ER, Schwartz K, Soto-Torres LE, Govender V. et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N Engl J Med. 2016;375:2121–2132. DOI: 10.1056/NEJMoa1506110

Nel A, Van Niekerk N, Kapiga S, Bekker LG, Gama C, Gill K, et al. Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. NEngl J Med. 2016; 375(22):2133–2143. DOI: 10.1056/NEJMoa1602046

Schlesinger E, Johengen D, Luecke E, Rothrock G, McGowan I, Van der Straten A, et al. A tunable, biodegradable, thin-film polymer device as a long-acting implant delivering tenofoviralafenamidefumarate for HIV pre-exposure prophylaxis. Pharm Res. 2016;33(7):1649–1656. DOI: 10.1007/s11095-016-1904-6

Klatt NR, Cheu R, Birse K, Zevin AS, Perner M, Noel-Romas L, et al. Vaginal bacteria modify HIV tenofovirmicrobicide efficacy in African women. Science. 2017; 356:938–945. DOI: 10.1126/science.aai9383

Anahtar MN, Byrne EH, Doherty KE, Bowman BA, Yamamoto HS, Soumillon M, et al. Cervicovaginal bacteria are a major modula-tor of host inflammatory responses in the female genital tract. Immunity. 2015;42(5):965–976. DOI: 10.1016/j.immuni.2015.04.019

Akil A, Agashe H, Dezzutti CS, Moncla BJ, Hillier SL, Devlin B, et al. Formulation and characterization of polymeric films containing combinations of antiretrovirals (ARVs) for HIV prevention. Pharm Res. 2015;32(2):458–468. DOI: 10.1007/s11095-014-1474-4

Heffron RA. Oral PrEP is efficacious for HIV prevention among wom-en with abnormal vaginal microbiota. Lancet HIV. 2017;4(10):449-456.

Hendrix CW, Chen BA, Guddera V, Hoesley C, Justman J, Naka-biito C, et al. MTN-001: Randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tis-sue and other compartments. PloS One. 2013;8(1):550–613. DOI: 10.1371/journal.pone.0055013

Hillier SL, Meyn L, Bunge K, Austin M, Moncla BJ, Dezzutti C, et al. Impact of vaginal microbiota on genital tissue and plasma concen-trations of tenofovir. CROL; 2017.

Oliveira P, Mascarenhas R, Lacroix C, Ferrer SR, C Oliverira RP, Cravo EA, et al. Braz J infect dis Candida species isolated from the vaginal mucosa of HIV-infected women in Salvador, Bahia, Brazil. 2011;15:239–244.

Lallar M, Nanda S, Nandal R. Lower genital tract infections in HIV-infected women: Can We Afford to Miss? J. Obstet. Gynaecol. 2015;65(1):45–49.

Sax P, Cohen C, Kuritzkes D. HIV essentials. Jones and Bartlett Learning. 2012;18–64.

Hall J, Hall B, Cockerell C. HIV/AIDS in the post-HAART era: Mani-festations, treatment, and epidemiology. USA: People's Medical Pub-lishing House. 2011; 389–403.

Greene W, Lange J. Sande's HIV/AIDS medicine: Medical management of AIDS. 2013;133–191.

Saag M, Chambers H, Eliopoulos G. The Sanford guide to HIV/AIDS therapy. Antimicrobial Therapy Inc. 2012; 214.